Zimmer Biomet Holdings, Inc. (ZBH) Stock Price & Analysis
Zimmer Biomet Holdings, Inc. (ZBH) rose 1.90% to USD 91.35 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
ZBH last closed at USD 89.65; the session ranged USD 90.47–92.31 on volume of 973,839 shares. Market capitalization is $17.67B, with a 52-week range of USD 79.12–108.29 (NYQ). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 91.35 |
|---|---|
| Change | ▲ 1.90% (up) |
| Previous Close | USD 89.65 |
| Open | USD 91.02 |
| Day Range | USD 90.47 – 92.31 |
| 52-Week Range | USD 79.12 – 108.29 |
| Volume | 973,839 shares |
| Market Cap | $17.67B |
| Exchange | NYQ |
Technical Analysis (ZBH)
Nexqual's technical model rates ZBH "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.28 (neutral) |
| vs SMA50 | Above (USD 87.64) |
| MACD | 0.66 (positive) |
Analyst Ratings (ZBH)
Wall Street analysts rate ZBH "Buy" based on 20 analysts, with a mean price target of USD 98.6 (range USD 83–130), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 98.6 |
| High Target | USD 130 |
| Low Target | USD 83 |
| Buy / Hold / Sell | 8 / 18 / 0 |
Earnings (ZBH)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 2.01 |
| Revenue Estimate | $2.14B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.09 vs est 1.86 ▲ beat |
| 2025-12-31 | USD 2.42 vs est 2.4 ▲ beat |
| 2025-09-30 | USD 1.9 vs est 1.87 ▲ beat |
| 2025-06-30 | USD 2.07 vs est 1.98 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (ZBH)
| Total Revenue | $8.41B |
|---|---|
| Revenue Growth (YoY) | +9.30% |
| Gross Margin | +70.18% |
| Operating Margin | +19.69% |
| Profit Margin | +9.05% |
| ROE | +6.07% |
| Debt / Equity | 59.83 |
| Current Ratio | 1.73 |
| Total Cash | $478.50M |
| Total Debt | $7.59B |
| Free Cash Flow | $1.04B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (ZBH)
Nexqual rates Zimmer Biomet Holdings, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 70%, operating 20% |
| Balance Sheet | Solid — $479M cash vs $7.59B debt |
| Cash Flow | Solid — FCF $1.04B, 13% margin |
| Efficiency | Mixed — ROE 6%, ROA 4.1% |
Ownership (ZBH)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +106.36% |
| Shares Outstanding | 193.46M |
| Float | 192.93M |
| Short % of Float | +8.02% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (ZBH)
Zimmer Biomet Holdings, Inc. is led by Ivan Tornos (age 50), President, CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 01:13 UTC.
| President, CEO & Chairman of the Board | Ivan Tornos (age 50) |
|---|---|
| Group President of Europe, Middle East & Africa | Wilfred van Zuilen (age 55) |
| Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | JehanZeb Noor (age 43) |
| Group President of Global Businesses & Americas | Kevin R. Thornal (age 51) |
| Interim CFO, VP, Controller & Chief Accounting Officer | Paul A. Stellato (age 50) |
Major Backers & Investors (ZBH)
Notable institutional backers of Zimmer Biomet Holdings, Inc. include Dodge & Cox Inc., Harris Associates L.P., Capital International Investors, according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 20.21% |
| Harris Associates L.P. | 9.76% |
| Capital International Investors | 4.71% |
| Price (T.Rowe) Associates Inc | 4.14% |
| Franklin Resources, Inc. | 2.82% |
| WASHINGTON MUTUAL INVESTORS FUND | 2.55% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.04% |
| BlackRock | 9.28% |
| State Street | 4.56% |
| Geode Capital | 2.78% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Zimmer Biomet Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
- It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
- The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues.
- It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IQV | IQVIA Holdings, Inc. | USD 208.05 | ▲ 4.8% |
| TFX | Teleflex Incorporated | USD 132.1 | ▼ 2% |
| COO | The Cooper Companies, Inc. | USD 70.31 | ▼ 0.27% |
| EW | Edwards Lifesciences Corporatio | USD 82.63 | ▼ 2.06% |
| FTV | Fortive Corporation | USD 62.31 | ▲ 3.42% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.